Switzerland-based MindMaze announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its MindMotion Go, a portable neurorehabilitation product, for launch in the United States.
MindMotion GO utilizes technology that is designed to be used by patients with mild to lightly severe neurological impairments, as well as those undergoing recovery phase. This product is an outpatient addition to the company’s MindMotion PRO, which received FDA approval in May 2017.
While MindMotion PRO is intended for in-patient treatment and patients with severe impairments, MinMotion GO is designed to assist patients with light and medium-severity neurologic decline who are able to receive rehabilitation at home. The platform features gamified activities covering task and motor functions in a 3-D setting and real-time audio-visual feedback enabling providers to assess a patient’s progress and modify treatments.
In the U.S., neurological deficits are the leading cause of long-term disability. Each year nearly 800,000 Americans suffer a stroke, which directly costs around $22.8 billion. According to a recent study, direct and indirect costs related to neurological diseases cost the U.S. an astonishing $800 billion yearly.
“Now that both MindMotion products have FDA clearance, MindMaze delivers a full spectrum of neuro-care solutions for both inpatient and outpatient recovery for patients in the United States,” said Tej Tadi, PhD, the CEO and founder of MindMaze, in a statement. “Our unique capability to safely and securely acquire data through our platform is essential for patient recovery and performance, and positions MindMaze as a powerhouse for the future of brain-machine interfaces. Beyond healthcare, this will enable powerful AI-based applications. We are working on a range of brain-tech initiatives at MindMaze to build the infrastructure for innovations to improve patients’ quality of life.”
The company made headlines in early 2016 when it announced a $100 million funding round.
It takes only 5minutes to set up, calibrated, and get the device ready to use. It is capable of tracking a user’s performance over time. The platform has so far only been available in Europe, where it has been tested by over 300 patients in the UK, Germany, Switzerland, and Italy. Both MindMotion Go and MindMotion Pro have obtained CE marks, and have so far been used by more than 1,300 patients in 45 hospitals since launching in 2013.
“One of the things we need to do is address cognitive issues and neurodegenerative diseases,” Tadi told MobiHealthNews. “So we started with movement deficits and then we move into cognitive deficits eventually neurodegenerative deficits. So we need to become the standard of care platform that eventually brings together VR, AR, neuroscience to help accelerate recovery across a wide range of indications.”